top of page

New Member: Welcome in our cluster to Anavo Therapeutics

We are happy to welcome in our cluster Anavo Therapeutics, the first company to systematically drug phosphatases, a rich target space considered undruggable for decades.

Anavo has attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications. Anavo is backed by blue-chip investors M Ventures, INKEF Capital, Taiho Ventures and Bioqube Ventures.

We are looking forward to see your active participation in the network!

You can find here more information about Anavo Therapeutics.


bottom of page